Furazolidone combination therapies for Helicobacter pylori infection in the United States

Alimentary Pharmacology and Therapeutics

Volumn 14, Issue 2, 2000, Pages 211-215

  Graham, D Y ^a   Osato, M S ^a   Hoffman, J ^a   Opekun, A R ^a   Anderson, S Y ^a   El Zimaity, H M T ^a  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; FURAZOLIDONE; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; TETRACYCLINE;

ABDOMINAL PAIN; ANOREXIA; ANTIMICROBIAL THERAPY; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COUGHING; DIARRHEA; DRUG EFFICACY; DYSPEPSIA; FEMALE; GRAM NEGATIVE INFECTION; HEADACHE; HEARTBURN; HELICOBACTER PYLORI; HUMAN; MALE; NAUSEA; PRIORITY JOURNAL; RASH; SIDE EFFECT; SOMNOLENCE; TASTE DISORDER; TREATMENT OUTCOME; UNITED STATES; VAGINA CANDIDIASIS; VERTIGO;

ANTI-ULCER AGENTS; CLARITHROMYCIN; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; FEMALE; FURAZOLIDONE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; OMEPRAZOLE; PROSPECTIVE STUDIES; TETRACYCLINE; TIME FACTORS; UNITED STATES;

EID: 0033966870     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2000.00640.x     Document Type: Article

References (28)

1. 1 Graham DY, Dore MP. Variability in the outcome of treatment of Helicobacter pylori infection: a critical analysis. In: Hunt RH, Tytgat GNJ, eds. Helicobacter Pylori Basic Mechanisms to Clinical Cure. Dordrecht: Kluwer Academic Publishers, 1998: 426-40.
2. 2 Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology 1998; 115: 1272-7.
3. 3 Megraud F. Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterology 1998; 115: 1278-82.
4. 4 Graham DY, Lew GM, Evans DG, Evans DJ Jr, Klein PD. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. A randomized controlled trial. Ann Intern Med 1991; 115: 266-9.
5. 5 Borody TJ, Cole P, Noonan S, et al. Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication. Med J Aust 1989; 151: 431-5.
6. 6 van Hulst RWM, Keller JJ, Rauws EA, Tytgat GNJ. Treatment of Helicobacter pylori infection in humans: a review of the world literature. Helicobacter 1996; 1: 6-19.
7. 7 Haas CE, Nix DE, Schentag JJ. In vitro selection of resistant Helicobacter pylori. Antimicrob Agents Chemother 1990; 34: 1637-41.
8. 8 Zheng ZT, Wang YB. Treatment of peptic ulcer disease with furazolidone. J Gastroenterol Hepatol 1992; 7: 533-7.
9. 9 Preobrazhenskii VN, Klimov NP, Katkov VI, Bazhanov VL, Degoeva BA, Kiselev SD. The treatment of patients with long-term nonhealing duodenal ulcers combined with chronic gastric erosions in the presence of Helicobacter pylori: Vrach Delo; 1991; 14: 87-99.
10. 10 Xiao SD, Liu WZ, Xia DH, et al. The efficacy of furazolidone and metronidazole in the treatment of chronic gastritis associated with Helicobacter (Campylobacter) pylori - a randomized double-blind placebo-controlled clinical trial. Hepato-Gastroenterology 1990; 37: 503-6.
11. 11 Segura AM, Gutierrez O, Otero W, et al. Furazolidine, amoxycillin, bismuth triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1997; 11: 529-32.
12. 12 van Zwet AA, Thijs JC, van der Wouden EJ, Kooy A. Low cure rate of Helicobacter pylori infection with omeprazole and furazolidone dual therapy for one week. Aliment Pharmacol Ther 1997; 11: 533-5.
13. 13 Morgan D, Kraft W, Bender M, Pearson A. Nitrofurans in the treatment of gastritis associated with Campylobacter pylori. The Gastrointestinal Physiology Working Group of Cayetano Heredia and The Johns Hopkins Universities. Gastroenterology 1988; 95: 1178-84.
14. 14 Goodwin CS. Antimicrobial treatment of Helicobacter pylori infection. Clin Infect Dis 1997; 25: 1023-6.
15. 15 Coelho LG, Passos MC, Chausson Y, Castro L. Five-day bismuth-free triple therapy for the eradication of Helicobacter pylori and reduction of duodenal ulcer relapse. Am J Gastroenterology 1991; 86: 971-5.
16. 16 Long DS, Li CM, Yang QG. Clinical observation on verrucous gastritis with combined therapy of traditional Chinese and Western medicine. Chung Kuo Chung Hsi I Chieh Ho Tsa Chih 1994; 14: 132-3.
17. 17 Coelho LG, Passos MC, Chausson Y, et al. Duodenal ulcer and eradication of Helicobacter pylori in a developing country. An 18-month follow-up study. Scand J Gastroenterol 1992; 27: 362-6.
18. 18 Ramirez-Ramos A, Gilman RH, Leon-Barua R, et al. Rapid recurrence of Helicobacter pylori infection in Peruvian patients after successful eradication. Gastrointestinal Physiology Working Group of the Universidad Peruana Cayetano Heredia and The Johns Hopkins University. Clin Infect Dis 1997; 25: 1027-31.
19. 19 Genta RM, Robason GO, Graham DY. Simultaneous visualization of Helicobacter pylori and gastric morphology: a new stain. Hum Pathol 1994; 25: 221-6.
20. 20 El-Zimaity HM, Ota H, Scott S, Killen DE, Graham DY. A new triple stain for Helicobacter pylori suitable for the autostainer: carbol fuchsin/Alcian blue/hematoxylin-eosin. Arch Pathol Lab Med 1998; 122: 732-6.
21. 21 Taylor DE, Jiang Q, Fedorak RN. Antibiotic susceptibilities of Helicobacter pylori strains isolated in the Province of Alberta. Can J Gastroenterol 1998; 12: 295-8.
22. 22 de Boer WA, Thys JC, Borody TJ, Graham DY, O'Morain C, Tytgat GN. Proposal for use of a standard side effect scoring system in studies exploring Helicobacter pylori treatment regimens. Eur J Gastroenterol Hepatol 1996; 8: 641-3.
23. 23 Fagan T. Quickbasic program for exact and mid-P confidence intervals for a binomial proportion. Comput Biol Med 1996; 26: 263-7.
24. 24 Howden A, Boswell P, Tovey F. In-vitro sensitivity of Campylobacter pyloridis to furazolidone - Letter. Lancet 1986; 2: 1035.
25. 25 Graham DY, Klein PD, Opekun AR, et al. In vivo susceptibility of Campylobacter pylori. Am J Gastroenterol 1989; 84: 233-8.
26. 26 de Boer WA. How to achieve a near 100% cure rate for H. pylori infection in peptic ulcer patients. A personal viewpoint. J Clin Gastroenterol 1996; 22: 313-6.
27. 27 van Hulst RW, van der Ende A, Homan A, Roorda P, Dankert J, Tytgat GN. Influence of metronidazole resistance on efficacy of quadruple therapy for Helicobacter pylori eradication. Gut 1998; 42: 166-9.
28. 28 Graham DY, Hoffman J, Osato MS, El-Zimaity HMT. BSS quadruple "salvage" therapy for patients with culture proven metronidazole-resistant Helicobacter pylori. Gastroenterology 1998; 114: A138(Abstract).